SPIA
LSTA icon

Steward Partners Investment Advisory’s Lisata Therapeutics LSTA Stock Holding History

Steward Partners Investment Advisory’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6
Closed -$21 – 3809
2024
Q2 		$21 Hold
6
– – ﹤0.01% 3591
2024
Q1 		$19 Hold
6
– – ﹤0.01% 3547
2023
Q4 		$16 Hold
6
– – ﹤0.01% 3479
2023
Q3 		$13 Buy
+6
New +$17 ﹤0.01% 3364

Other funds holding LSTA

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CW
Cook Wealth Raleigh, North Carolina $206M AUM 4.73% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Steward Partners Investment Advisory's LSTA Position: Q3 2024 in Review

Steward Partners Investment Advisory sold out of Lisata Therapeutics (LSTA) in Q3 2024, closing a stake of 6 shares — an estimated $21 sold.

Steward Partners Investment Advisory first reported a position in LSTA in Q3 2023 and held it in 4 quarters. The position peaked at $21 in Q2 2024. 20 funds tracked by Wall St. Rank hold LSTA as of Q3 2024.

  • Steward Partners Investment Advisory reported no remaining Lisata Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 6 Lisata Therapeutics shares in Q3 2024, an estimated $21.
  • Steward Partners Investment Advisory first reported a position in Lisata Therapeutics in Q3 2023 and held it in 4 quarters.
  • Steward Partners Investment Advisory's Lisata Therapeutics position peaked at $21 in Q2 2024.
  • 20 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q3 2024.

Based on Steward Partners Investment Advisory's 13F filing for Q3 2024, filed 14 Nov 2024.